Key Highlights

  • On 29 October 2026, EVE Health Group Limited (ASX:EVE) was quoted at AUD 0.014, with the daily change shown as unchanged. This article covers libbo clinical study preparation, study timing and regulatory steps and the company’s wider disclosures.
  • EVE advanced the Libbo pilot study protocol and engaged a clinical organisation and site.
  • Testing of its apixaban formulation showed solubility above 50 mg/mL, alongside leadership changes.

For EVE Health Group Limited (ASX:EVE), the latest filing describes changes across the business and its financial position. On 29 October 2026, EVE Health Group Limited (ASX:EVE) was quoted at AUD 0.014, with the daily change shown as unchanged. EVE advanced the Libbo pilot study protocol and engaged a clinical organisation and site. Testing of its apixaban formulation showed solubility above 50 mg/mL, alongside leadership changes. The disclosures also address apixaban solubility results and operating cash and other programs.

Libbo Clinical Study Preparation

EVE Health Group progressed its Libbo pilot bioequivalence program during the June 2026 quarter. Libbo is a 10-milligram oral-soluble film containing vardenafil. The company finalised the pilot-study protocol and engaged a contract research organisation and clinical site. The pilot was designed to compare Libbo with an approved reference product in healthy male volunteers. EVE described the pilot study as preparation for a later pivotal bioequivalence program, rather than completion of a regulatory registration or a demonstrated clinical efficacy outcome.

Study Timing and Regulatory Steps

EVE updated its expected pilot dosing timeline to Q4 2026, with data anticipated in early 2027. Management reported remaining preparation involving reference-product testing and regulatory submission and review. The company described the additional work as part of the normal process ahead of dosing. It also indicated that a subsequent pivotal study would depend on satisfactory pilot outcomes. At the time of the June update, the proposed study milestones were future events; no patient-dosing completion or pivotal-study result was reported.

Apixaban Solubility Results

The company reported apixaban solubility of more than 50 milligrams per millilitre using its proprietary solubilisation technology, against a baseline aqueous solubility of approximately 0.6 milligrams per millilitre. Apixaban is the active ingredient used in an anticoagulant medicine. The reported figure arose from formulation testing and supported the company’s development work, for which a provisional patent application had been lodged. This technical result does not constitute a clinical outcome, approval or evidence of a marketed reformulated medicine.

Leadership and Operating Structure

EVE appointed Ben Rohr as chief executive officer, effective 27 April 2026. He previously served as chief operating officer and had been involved in integration and commercial programs. The company linked the leadership appointment with its preparation for regulatory development and potential partnerships across the product portfolio. The quarterly disclosure also described a capital-light and partner-led approach to licensing and supply activities, although it did not announce a new approved therapy or completed regulatory registration.

Operating Cash and Other Programs

The June-quarter Appendix 4C recorded customer receipts of AUD 266,000 and identified spending on research and development, product manufacturing, administration and staff. Payments to related parties totalled AUD 83,000, including AUD 72,000 in directors’ fees and superannuation and AUD 11,000 in office overheads paid to an associated service provider. The company also discussed its Dyspro program and broader reformulation pipeline, with future study, intellectual-property and licensing activities subject to their respective development and regulatory steps.

Key Insights

Overall, EVE Health Group Limited reported eVE advanced the Libbo pilot study protocol and engaged a clinical organisation and site. testing of its apixaban formulation showed solubility above 50 mg/mL, alongside leadership changes. The announcement also addresses apixaban solubility results, leadership and operating structure and operating cash and other programs. These are company-reported results and planned activities for their stated periods; announced targets, proposed transactions and pending approvals remain distinct from completed outcomes.